David Pernock
Chairman and Chief Executive Officer

David Pernock, Chairman of the Board and CEO, joined Fibrocell Science with extensive leadership experience in healthcare sales and commercialization, building business units, partnerships, and brands. Prior to joining Fibrocell, he served as Senior Vice President, Pharmaceuticals, Vaccines (Biologics), Oncology, Acute Care and HIV at GlaxoSmithKline. Over a long career at GlaxoSmithKline, Mr. Pernock was promoted numerous times to levels of increasing responsibility including vice president of Marketing, Pharmaceuticals; Vice President of Sales and Marketing, Oncology; Vice President of Managed Care; and, Vice President of Sales. Mr. Pernock holds a BS in Business Administration from Arizona State University. He serves on many philanthropic organizations.

Declan Daly
Chief Operating Officer and Chief Financial Officer

Declan Daly was named Chief Operating Officer and Chief Financial Officer of Fibrocell Science, Inc. in September 2009. Prior to the reorganization of Isolagen, Inc. as Fibrocell, he had served as Chief Executive Officer of Isolagen. He originally joined Isolagen as Chief Financial Officer (CFO) and Executive Vice President – Europe in June 2006, and was promoted to Chief Operating Officer and CFO in June 2007. Prior to joining Isolagen, Mr. Daly spent more than seven years with Inamed Corporation and most recently served as CFO. Prior to becoming CFO, Mr. Daly served as Inamed’s Senior Vice President, Corporate Controller and Principal Accounting Officer, and previously as Vice President of Finance & Administration of Inamed International Corp. based in Europe. Mr. Daly holds a BA in Management Science and Industrial Systems Studies from Trinity College in Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland.

Elizabeth A. Browning
Executive Vice President, Marketing & Sales

Mrs. Browning, Executive Vice President, Marketing & Sales, was founder and chief executive officer of LLuminari, an innovative health education company for women and those they care for. The company transitioned to a consumer facing site, BeWell.com, which was acquired in 2011. Prior to founding LLuminari, Elizabeth was President, DuPont Consumer Health, a division of DuPont’s Nutrition & Health strategic business unit. During her 20 year career with the DuPont company, Elizabeth held a variety of leadership positions in industries ranging from biotechnology to pharmaceuticals and textile fibers.

John Maslowski
Vice President, Operations

Mr. Maslowski joined predecessor company Isolagen in 2005 and has since held various management positions in Manufacturing and Quality Assurance with the Company. Prior to Isolagen, Mr. Maslowski was employed at Wyeth Pharmaceuticals from 2001 to 2005, serving most recently as Quality Assurance Investigations Manager in support of manufacturing. Previously, Mr. Maslowski held positions with Merck Research Laboratories and Teva Pharmaceuticals. Mr. Maslowski holds a BS in Biology from Ursinus College and MS in Biology from Villanova University. In addition, he is a Certified Quality Auditor through the American Society for Quality.

Jeanne Novak, Ph.D.
Acting Vice President, Clinical/Regulatory Operations

Dr. Novak is a Founder and Principal of CBR International, a scientifically-based biotech development company. She got her Ph.D. in Experimental Pathology (Cell Biology) from University of Utah Medical School, and served as a FDA Senior scientist, credentialed Inspector and expert advisor to FDA Center Directors. Dr. Novak also serves as Acting Senior Vice President to biotech companies and she is pivotal in several recent FDA approvals. Currently, she is serving as the Authorized U.S. Regulatory Representative for Fibrocell.

James Merritt, M.D.
Chief Medical Advisor

Dr. Merritt is the Chief Medical Officer at CBR International and is serving as the Medical Monitor and Clinical Advisor for Fibrocell. He is a Board-certified medical oncologist with extensive clinical, clinical research and management experience across several types of products and clinical indications. He held Chief and Senior Vice President positions at IDEC Pharmaceuticals (now Biogen Idec), Viagene Inc, and Introgen. Dr. Merritt successfully advanced novel biological modalities such as therapeutic monoclonal antibodies and gene transfer technologies in advanced clinical studies. He graduated from Johns Hopkins University and received his MD from the University of Vermont.

Laura Campbell
Vice President, Planning

Laura Campbell was named Vice President, Planning in 2011. Mrs. Campbell joined Fibrocell Science with 19 years of human resource and operational experience in the healthcare industry. Prior to joining Fibrocell Science, Mrs. Campbell was employed at GlaxoSmithKline and held various positions in global human resources and commercial operations. Mrs. Campbell holds a BS in Human Resources from LaSalle University and MS in Human Organizational Science from Villanova University.

Karen Donhauser
Vice President, Quality

Karen Donhauser joined Fibrocell Science in 2005 as the Manager of Quality Control and currently holds the title of Vice President of Quality. Prior to joining Fibrocell, Karen worked for Wyeth Pharmaceuticals for eight years, holding positions in both Quality Control and Manufacturing. She served most recently as Manager of the Microbiology Laboratory in their sterile injectable penicillin facility and was responsible for all microbiological release testing on finished product, with emphasis on sterility assurance. Karen holds a Bachelor of Science degree in Biology from Juniata College.